Tan et al. reported an aptamer-based breast cancer treatment that combines a chemosensitizer and an anti-cancer agent by co-delivering a peptide that specifically inhibits heat shock protein 70 (HSP70), a cytoprotective protein overexpressed in cancer, an aptamer that targets the oncoprotein mucin-1 (MUC-1), and Dox [158]. The gene discussed is MUC1; the disease is cancer.